AstraZeneca enters agreement with KYM for CMG901
23 February 2023 07:00 GMT AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate CMG901 expands AstraZeneca's commitment in gastric cancer AstraZeneca and KYM Biosciences Inc.[i] have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. CMG901